Heptares Therapeutics Appoints Dr Barry Kenny as Chief Business Officer

06-Oct-2009 - United Kingdom

Heptares Therapeutics Ltd has appointed Dr Barry Kenny as its Chief Business Officer to focus on business development and strategic alliances based on the Company’s drug discovery capabilities and its StaR™ technology.

Barry has over 24 years’ research and management experience in the pharmaceutical and biotechnology industry, most recently as Vice President, Drug Discovery at Takeda Cambridge with overall responsibility for IND discovery. Prior to this, he was Commercial Director at Paradigm Therapeutics where he was responsible for several company-transforming deals, including the broad CNS collaboration with Takeda in 2005. He was also instrumental in the subsequent acquisition of Paradigm by Takeda in 2007.

Barry co-founded Cambridge Drug Discovery (CDD) in 1997, and was Director of Business Development for Biofocus following its merger with CDD in 2001, establishing a wide range of international deals and collaborations. Before this, he was at Pfizer Central Research and was responsible for the successful discovery and progression of several drug candidates into clinical development. He also spent eight years at Syntex Research Scotland, where he completed his PhD and post-doctoral studies.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances